CV-19: Glaxo gets something right at last

[JohnD]

"Data from 583 patients shows 85% reduction in hospitalisation or death"

https://www.ft.com/content/49bdda63-46d1-4ce5-b25c-030bd6f2e8f5

"GlaxoSmithKline plans to apply for emergency use authorisation for an experimental Covid-19 treatment after initial clinical trial results showed an 85 per cent reduction in hospitalisation or death.

GSK, which developed the antibody treatment with Vir Biotechnology, said separate lab tests of the drug suggested it was also effective against some of the virus variants in circulation.

An independent data monitoring committee recommended stopping the GSK/Vir Biotechnology trial early due to evidence of “profound efficacy”, the companies said on Thursday. That recommendation was based on an interim analysis of data from 583 non-hospitalised patients, which found an 85 per cent reduction in hospitalisation or death compared with a placebo."

 

[JohnD]

January's announcement:

https://www.gsk.com/en-gb/media/pre...-vir-7832-in-the-early-treatment-of-covid-19/

 

[JohnD]

Yesterday's announcement:

https://www.gsk.com/en-gb/media/pre...h-in-early-treatment-of-adults-with-covid-19/

 

[IT Minion]

Hopefully it'll also be as effective when used later, my skim of that study says it is being tested when used early.

Which is fine but it's also a class of treatment that's normally very expensive and not easily produced. An 85% reduction is great, but less helpful when you can only treat a handful of people.